Literature DB >> 1670442

Prevention of deep vein thrombosis after total hip replacement. The effect of low-molecular-weight heparin with spinal and general anaesthesia.

A Planès1, N Vochelle, M Fagola, J Feret, M Bellaud.   

Abstract

Enoxaparin, a low-molecular-weight heparin, has been used together with spinal or general anaesthesia in a prospective, randomised study of 188 consecutive elective hip replacements. Bilateral venography was performed on all patients on day 13 after operation. Group I (65 patients) received spinal anaesthesia and no immediate injection of enoxaparin. Group II (61 patients) received spinal anaesthesia and 20 mg of enoxaparin one hour after the onset of anaesthesia. Group III (62 patients) was operated on under general anaesthesia and received 40 mg of enoxaparin 12 hours prior to surgery. This group acted as the control group. In all three groups, 40 mg of enoxaparin was given 12 hours after the end of surgery and continued on a once-daily basis. Proximal DVT occurred in 6% of group I, 6.7% of group II and 6.5% of group III, not a significant difference. Distal DVT was present in 11% of group I, 5% of group II and 0% of group III; this was a highly significant difference (p = 0.007). Tolerance was good and the incidence of bleeding low in the three groups. Our results confirm the low rate of DVT in patients operated on under general anaesthesia with the standard procedure of 40 mg of enoxaparin on a once-daily basis started pre-operatively. The 40 mg-dose is also safe and effective in association with spinal anaesthesia if half the dose (20 mg) is injected an hour after the lumbar puncture.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670442

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  10 in total

Review 1.  Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials.

Authors:  A Rodgers; N Walker; S Schug; A McKee; H Kehlet; A van Zundert; D Sage; M Futter; G Saville; T Clark; S MacMahon
Journal:  BMJ       Date:  2000-12-16

2.  General versus spinal anesthesia in joint arthroplasties.

Authors:  Crispiana Cozowicz; Stavros G Memtsoudis
Journal:  Ann Transl Med       Date:  2015-07

Review 3.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

4.  The effect of spinal anesthesia on blood transfusion rate in total joint arthroplasty.

Authors:  Saifudin Rashiq; Barry A Finegan
Journal:  Can J Surg       Date:  2006-12       Impact factor: 2.089

5.  Perioperative comparative effectiveness of anesthetic technique in orthopedic patients.

Authors:  Stavros G Memtsoudis; Xuming Sun; Ya-Lin Chiu; Ottokar Stundner; Spencer S Liu; Samprit Banerjee; Madhu Mazumdar; Nigel E Sharrock
Journal:  Anesthesiology       Date:  2013-05       Impact factor: 7.892

6.  Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.

Authors:  P F Leyvraz; F Bachmann; J Hoek; H R Büller; M Postel; M Samama; M D Vandenbroek
Journal:  BMJ       Date:  1991-09-07

Review 7.  Prevention and treatment of venous thromboembolism.

Authors:  G F Pineo; R D Hull
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

8.  Comparative perioperative outcomes associated with neuraxial versus general anesthesia for simultaneous bilateral total knee arthroplasty.

Authors:  Ottokar Stundner; Ya-Lin Chiu; Xuming Sun; Madhu Mazumdar; Peter Fleischut; Lazaros Poultsides; Peter Gerner; Gerhard Fritsch; Stavros G Memtsoudis
Journal:  Reg Anesth Pain Med       Date:  2012 Nov-Dec       Impact factor: 6.288

9.  General anesthesia vs spinal anesthesia for patients undergoing total-hip arthroplasty: A meta-analysis.

Authors:  Xiang Pu; Jian-Ming Sun
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

10.  Hip fracture surgery: does type of anesthesia matter?

Authors:  Rizwan Haroon Rashid; Adil Aijaz Shah; Amarah Shakoor; Shahryar Noordin
Journal:  Biomed Res Int       Date:  2013-06-02       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.